Martin S Hirsch

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc The future of HIV treatment
    Martin S Hirsch
    Department of Medicine, Massachusetts General Hospital, Boston MA, USA
    J Acquir Immune Defic Syndr 60:S39-40. 2012
  2. ncbi request reprint Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel
    M S Hirsch
    Harvard Medical School, Boston, MA, USA
    JAMA 279:1984-91. 1998
  3. ncbi request reprint Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel
    M S Hirsch
    Harvard Medical School, Boston, Mass, USA
    JAMA 283:2417-26. 2000
  4. doi request reprint Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
    Martin S Hirsch
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 47:266-85. 2008
  5. pmc TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, 65 Landsdowne St, Room 419, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 49:3483-5. 2005
  6. pmc Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 47:3644-6. 2003
  7. ncbi request reprint Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
    Gregory K Robbins
    Harvard Medical School, Boston, USA
    N Engl J Med 349:2293-303. 2003
  8. ncbi request reprint Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection
    Cecile L Tremblay
    Massachusetts General Hospital and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    AIDS 17:1086-9. 2003
  9. ncbi request reprint Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
    Martin S Hirsch
    Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 37:113-28. 2003
  10. ncbi request reprint Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection
    Martin S Hirsch
    Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Clin Infect Dis 37:1119-24. 2003

Collaborators

Detail Information

Publications20

  1. pmc The future of HIV treatment
    Martin S Hirsch
    Department of Medicine, Massachusetts General Hospital, Boston MA, USA
    J Acquir Immune Defic Syndr 60:S39-40. 2012
    ....
  2. ncbi request reprint Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel
    M S Hirsch
    Harvard Medical School, Boston, MA, USA
    JAMA 279:1984-91. 1998
    ..To review current knowledge of the biology and clinical implications of human immunodeficiency virus (HIV) resistance to antiretroviral drugs, describe assays for measuring resistance, and assess their use in clinical practice...
  3. ncbi request reprint Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel
    M S Hirsch
    Harvard Medical School, Boston, Mass, USA
    JAMA 283:2417-26. 2000
    ..The International AIDS Society-USA sought to update prior recommendations to provide guidance for clinicians regarding indications for HIV-1 resistance testing...
  4. doi request reprint Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
    Martin S Hirsch
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 47:266-85. 2008
    ..As the roll out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype B and non-subtype B strains of HIV will become increasingly important...
  5. pmc TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, 65 Landsdowne St, Room 419, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 49:3483-5. 2005
    ..Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted...
  6. pmc Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 47:3644-6. 2003
    ..53 to 1.06 at 95% inhibitory concentrations. These studies suggest that a combination of T-20 and DAPD might be useful in the treatment of antiretroviral drug-experienced patients...
  7. ncbi request reprint Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
    Gregory K Robbins
    Harvard Medical School, Boston, USA
    N Engl J Med 349:2293-303. 2003
    ..The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies...
  8. ncbi request reprint Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection
    Cecile L Tremblay
    Massachusetts General Hospital and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    AIDS 17:1086-9. 2003
    ..Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted...
  9. ncbi request reprint Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
    Martin S Hirsch
    Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 37:113-28. 2003
    ..Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation...
  10. ncbi request reprint Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection
    Martin S Hirsch
    Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Clin Infect Dis 37:1119-24. 2003
    ..Hyperbilirubinemia (experienced by 31% of subjects), nausea (17%), abdominal pain (14%), and nephrolithiasis (13%) were the most common drug-related adverse events during the extension...
  11. ncbi request reprint Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384
    Rajesh T Gandhi
    Massachusetts General Hospital, Boston, MA, USA
    J Acquir Immune Defic Syndr 42:426-34. 2006
    ..To assess the effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy (ART)...
  12. ncbi request reprint Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
    ..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
  13. ncbi request reprint Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus
    Rajesh T Gandhi
    Infectious Diseases Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Infect Dis 37:1693-8. 2003
    ..Moreover, it suggests that, despite initially impaired viral fitness, a transmitted HIV-1 isolate with multiple drug resistance mutations can evolve to develop increased RC and significant pathogenicity...
  14. pmc Antiretroviral therapy in the clinic
    Athe M N Tsibris
    Massachusetts General Hospital, Harvard Medical School, 65 Landsdowne St, Cambridge, MA 02139, USA
    J Virol 84:5458-64. 2010
    ....
  15. pmc pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo
    J J Eron
    Harvard Medical School, Boston, Massachusetts 02129
    Antimicrob Agents Chemother 37:1480-7. 1993
    ..The results of the in vitro experiments and characterization of clinical isolates suggest that there are differences in the functional effects of these AZT and ddI resistance mutations...
  16. ncbi request reprint Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy
    A Seth
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Infect Dis 183:722-9. 2001
    ..However, the overall level of antigen-specific cells that are capable of differentiating into effectors remains stable, and the recognition of new epitopes may occur...
  17. doi request reprint Initiating therapy: when to start, what to use
    Martin S Hirsch
    Massachusetts General Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA
    J Infect Dis 197:S252-60. 2008
    ..Some new antiretroviral drugs under study, particularly integrase inhibitors, may prove useful in treatment-naive patients...
  18. pmc Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts 02114, USA
    Antimicrob Agents Chemother 46:1336-9. 2002
    ..These findings suggest that SCH-C may be a useful anti-HIV drug in combination regimens and that a combination of chemokine coreceptor/fusion inhibitors may be useful in the treatment of multidrug-resistant viruses...
  19. ncbi request reprint In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs
    S Rusconi
    Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    Antivir Ther 5:199-204. 2000
    ..This compound is a promising new candidate in a receptor-based approach to HIV-1 infection in conjunction with currently available combination antiretroviral drug therapies...
  20. pmc Monitoring HIV treatment in developing countries
    Serena P Koenig
    Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    BMJ 332:602-4. 2006